Endo Health recent sell-off a buying opportunity, says JPMorgan JPMorgan views the recent pullback in shares of Endo Health as a buying opportunity. The firm sees 2014 as a trough earnings year for Endo and says the company's earnings guidance is "highly beatable." JPMorgan reiterates an Overweight rating on the stock with an $85 price target.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.